Gufic Biosciences share news, announcements and annual reports
NSE: GUFICBIOBSE: 509079Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 28 Oct 2026. Previous close ₹420.45.
28 Oct: open ₹420.95, high ₹430.70, low ₹414.15
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,249 Cr959th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 57.85
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.39
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.02%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 11.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.58
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,56,95560.7% delivered
Gufic Biosciences share news and announcements
608 announcements, routine notices left out, newest first. Page 2 of 13.
Aug 2025
13 Aug · Board meeting
8 Aug · Analysts
Jul 2025
Jun 2025
30 Jun · General Updates
May 2025
30 May · Board meeting
26 May · Analysts
Apr 2025
Mar 2025
Feb 2025
20 Feb · Analysts
14 Feb · Results
14 Feb · Board meeting
4 Feb · Analysts
3 Feb · General Updates
Jan 2025
31 Jan · General Updates
14 Jan · General Updates
7 Jan · Meeting
Dec 2024
31 Dec · General Updates
27 Dec · Updates
27 Dec · Board meeting
Nov 2024
22 Nov · Management
22 Nov
14 Nov · Board meeting
14 Nov · Results
13 Nov · Analysts
12 Nov · Analysts
4 Nov · Legal
The exchange asked on 4 Nov 2024
Oct 2024
Sep 2024
25 Sep · Meeting
25 Sep · Management
25 Sep · Board meeting
Aug 2024
31 Aug · Corporate action